An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line

The rapid evolution of new SARS-CoV-2 variants poses a continuing threat to human health. Vaccination has become the primary therapeutic intervention. The goal of the current work was the construction of immunogenic virus-like particles (VLPs). Here, we describe a human cell line for cost-efficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirschberg, Stefan, Ghazaani, Fatemeh, Ben Amor, Ghada, Pydde, Markus, Nagel, Alexander, Germani, Saveria, Monica, Lara, Schlör, Anja, Bauer, Hannes, Hornung, Jane, Voetz, Michael, Dwai, Yamen, Scheer, Benjamin, Ringel, Frauke, Kamal-Eddin, Omar, Harms, Christoph, Füner, Jonas, Adrian, Lorenz, Pruß, Axel, Schulze-Forster, Kai, Hanack, Katja, Kamhieh-Milz, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535180/
https://www.ncbi.nlm.nih.gov/pubmed/37766145
http://dx.doi.org/10.3390/vaccines11091469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535180/
https://www.ncbi.nlm.nih.gov/pubmed/37766145
http://dx.doi.org/10.3390/vaccines11091469

Ejemplares similares